OOIR: Observatory of International Research

Papers

(The H4-Index of Blood is 93. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
COVID-19 and its implications for thrombosis and anticoagulation	1711
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome	1030
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection	949
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data	823
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN	814
Platelet gene expression and function in patients with COVID-19	711
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19	562
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	516
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	515
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial	460
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients	456
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial	420
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party	306
Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis	288
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study	279
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition	275
Venous thromboembolism in cancer patients: a population-based cohort study	274
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report	265
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients	243
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19	237
Outcomes of COVID-19 in patients with CLL: a multicenter international experience	235
Pediatric hemophagocytic lymphohistiocytosis	220
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure	204
Overview of Castleman disease	201
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	197

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS	189
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era	188
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	182
Postdischarge thrombosis and hemorrhage in patients with COVID-19	181
Glucose-6-phosphate dehydrogenase deficiency	171
Langerhans cell histiocytosis	168
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial	167
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma	166
The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice	160
Antibody-induced procoagulant platelets in severe COVID-19 infection	158
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies	155
Postdischarge venous thromboembolism following hospital admission with COVID-19	154
NPM1-mutated acute myeloid leukemia: from bench to bedside	151
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI	150
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C	146
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	146
Therapeutic options in VEXAS syndrome: insights from a retrospective series	145
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study	140
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set	138
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	137
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA	136
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies	134
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma	134
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	133
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome	131
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry	131
Prothrombotic immune thrombocytopenia after COVID-19 vaccination	130
Management of AL amyloidosis in 2020	129
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes	126
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results	125
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2	121
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study	120
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose	119
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset	118
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	118
Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion	115
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy	115
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial	115
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome	114
High total metabolic tumor volume at baseline predicts survival independent of response to therapy	113
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms	112
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype	112
Developmental trajectory of prehematopoietic stem cell formation from endothelium	112
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis	111
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study	110
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies	110
Diamond-Blackfan anemia	109
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines	108
Use of convalescent plasma in hospitalized patients with COVID-19: case series	107
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation	107

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results	106
Association of clonal hematopoiesis with chronic obstructive pulmonary disease	105
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma	105
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein	105
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells	103
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study	103
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis	100
Redefining outcomes in immune TTP: an international working group consensus report	99
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression	99
Erdheim-Chester disease	97
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy	96
Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults	96
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein	95
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD	95
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma	94
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity	94
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial	93
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination	93
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial	93
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma	93